The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out ...

A full-year 2024 trading update for Arecor Therapeutics shows revenue was up to £5.1million (2023: £4.6m) while cash and cash ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Another drugs that may be used off-label for GHI include Xeris' Gvoke brand of glucagon in pre-filled syringe and pen injector formulations, which was approved in 2019 as a hypoglycaemia rescue ...

Beta Bionics’ IPO marks one of the largest public offerings for an Orange County-based company in over three years, second ...

In the US, Baqsimi is now competing head-to-head with Xeris’ Gvoke, pre-filled syringe and pen injector formulations of glucagon that don’t require the mixing steps and can be used in patients ...

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.